InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| C14-Tri-LAN-Gly | Determining the metabolic impact of postbiotics in mice. | 2022 | STAR Protoc. | Anhê F.F. et al. | DOI: 10.1016/j.xpro.2021.101098 |
| R848 VacciGrade™ | Celastrol gel ameliorates imiquimod-induced psoriasis-like dermatitis in mice... | 2022 | Biomed Pharmacother | Liu L. et al. | DOI: 10.1016/j.biopha.2022.112644 |
| Puromycin | The deubiquitinase Usp27x as a novel regulator of cFLIP L protein expression ... | 2022 | Apoptosis | Dold M.N. et al. | DOI: 10.1007/s10495-021-01706-9 |
| HKMT | Identification of anti-lipoarabinomannan antibodies against mannan core and t... | 2022 | Tuberculosis (Edinb) | Nakayama H. et al. | DOI: 10.1016/j.tube.2022.102165 |
| THP1-Blue™ NF-κB Cells | TNF-α response in macrophages depends on clinical Legionella pneumophila isol... | 2022 | Virulence | Guillemot J. et al. | DOI: 10.1080/21505594.2021.2022861 |
| QUANTI-Blue™ | TNF-α response in macrophages depends on clinical Legionella pneumophila isol... | 2022 | Virulence | Guillemot J. et al. | DOI: 10.1080/21505594.2021.2022861 |
| CL097 | Innate immune deficiencies are associated with severity and poor prognosis in... | 2022 | Sci Rep | Peyneau M. et al. | DOI: 10.1038/s41598-021-04705-7 |
| Puromycin | Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. | 2021 | Nature | Carreño J.M. et al. | DOI: 10.1038/s41586-022-04399-5 |
| Normocin® - Antimicrobial Reagent | Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. | 2021 | Nature | Carreño J.M. et al. | DOI: 10.1038/s41586-022-04399-5 |
| Puromycin | The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and al... | 2022 | Cell Mol Life Sci | Schreiber A. et al. | DOI: 10.1007/s00018-021-04085-1 |
| Bafilomycin A1 | Pharmacological agents targeting autophagy and their effects on lipolysis in ... | 2022 | Mol Cell Endocrinol | Xu Q. et al. | DOI: 10.1016/j.mce.2022.111555 |
| 3-Methyladenine | Pharmacological agents targeting autophagy and their effects on lipolysis in ... | 2022 | Mol Cell Endocrinol | Xu Q. et al. | DOI: 10.1016/j.mce.2022.111555 |
| ODN 2006 (ODN 7909) | Soluble antigens derived from Coxiella burnetii elicit protective immunity in... | 2021 | Cell Rep Med | Gregory A.E. et al. | DOI: 10.1016/j.xcrm.2021.100461 |
| TLR4-based adjuvant - MPLA-SM VacciGrade™ | Soluble antigens derived from Coxiella burnetii elicit protective immunity in... | 2021 | Cell Rep Med | Gregory A.E. et al. | DOI: 10.1016/j.xcrm.2021.100461 |
| ODN 2007 - TLR9 ligand | Soluble antigens derived from Coxiella burnetii elicit protective immunity in... | 2021 | Cell Rep Med | Gregory A.E. et al. | DOI: 10.1016/j.xcrm.2021.100461 |
| Alhydrogel® adjuvant 2% | Soluble antigens derived from Coxiella burnetii elicit protective immunity in... | 2021 | Cell Rep Med | Gregory A.E. et al. | DOI: 10.1016/j.xcrm.2021.100461 |
| Quil-A® adjuvant | Soluble antigens derived from Coxiella burnetii elicit protective immunity in... | 2021 | Cell Rep Med | Gregory A.E. et al. | DOI: 10.1016/j.xcrm.2021.100461 |
| ODN 1826 - TLR9 ligand | Soluble antigens derived from Coxiella burnetii elicit protective immunity in... | 2021 | Cell Rep Med | Gregory A.E. et al. | DOI: 10.1016/j.xcrm.2021.100461 |
| pINFUSE-hIgG2-Fc | Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement w... | 2022 | Nat Commun | Du Y. et al. | DOI: 10.1038/s41467-021-27936-8 |
| FSL-1 | C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and ... | 2022 | Nat Commun | Park I. et al. | DOI: 10.1038/s41467-021-27862-9 |